82PD - European harmonization study for the immunohistochemical detection of ALK-rearranged NSCLC (on behalf of all 16 participating institutes enrolled in...

Date 27 March 2014
Event ELCC 2014
Session Poster Discussion 1
Topics Non-Small-Cell Lung Cancer, Metastatic
Pathology/Molecular Biology
Personalised Medicine
Presenter Maximilian von Laffert
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors A. Warth1, M. von Laffert2, R. Penzel1, P. Schirmacher3, D. Lenze4, M. Hummel2, M. Dietel2
  • 1Heidelberg, Pathology, Heidelberg/DE
  • 2Institue Of Pathology Charité, Charite Berlin Mitte, 10117 - Berlin/DE
  • 3Pathology, University Hospital, Heidelberg/DE
  • 4Pathology, Pathology Berlin, Berlin/DE


The reliable identification of ALK-gene rearranged NSCLC is crucial for the treatment with ALK-inhibitors. Even though fluorescence in-situ hybridization (FISH) is regarded as the diagnostic gold standard, studies based on immunohistochemistry (IHC) seem promising. However, such an approach is only applicable if it is validated and standardized for multi-centre use.